IL218637A0 - Dosage regimen for administering an epcamxcd3 bispecific antibody - Google Patents

Dosage regimen for administering an epcamxcd3 bispecific antibody

Info

Publication number
IL218637A0
IL218637A0 IL218637A IL21863712A IL218637A0 IL 218637 A0 IL218637 A0 IL 218637A0 IL 218637 A IL218637 A IL 218637A IL 21863712 A IL21863712 A IL 21863712A IL 218637 A0 IL218637 A0 IL 218637A0
Authority
IL
Israel
Prior art keywords
administering
bispecific antibody
dosage regimen
epcamxcd3 bispecific
epcamxcd3
Prior art date
Application number
IL218637A
Other languages
English (en)
Original Assignee
Micromet Ag
Gerhard Zugmeier
Peter Kufer
Dominik Ruttinger
Sabine Kaubitzsch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Micromet Ag, Gerhard Zugmeier, Peter Kufer, Dominik Ruttinger, Sabine Kaubitzsch filed Critical Micromet Ag
Publication of IL218637A0 publication Critical patent/IL218637A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL218637A 2009-09-18 2012-03-14 Dosage regimen for administering an epcamxcd3 bispecific antibody IL218637A0 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US24365109P 2009-09-18 2009-09-18
EP09170715 2009-09-18
US34414710P 2010-06-01 2010-06-01
EP10164596 2010-06-01
PCT/EP2010/063795 WO2011033105A1 (en) 2009-09-18 2010-09-20 Dosage regimen for administering an epcamxcd3 bispecific antibody

Publications (1)

Publication Number Publication Date
IL218637A0 true IL218637A0 (en) 2012-05-31

Family

ID=43127167

Family Applications (1)

Application Number Title Priority Date Filing Date
IL218637A IL218637A0 (en) 2009-09-18 2012-03-14 Dosage regimen for administering an epcamxcd3 bispecific antibody

Country Status (15)

Country Link
US (1) US20120244161A1 (https=)
EP (1) EP2477653A1 (https=)
JP (1) JP2013505223A (https=)
KR (1) KR20120083359A (https=)
CN (1) CN102711825A (https=)
AU (1) AU2010297258A1 (https=)
BR (1) BR112012008345A2 (https=)
CA (1) CA2774732A1 (https=)
IL (1) IL218637A0 (https=)
IN (1) IN2012DN03172A (https=)
MX (1) MX2012003175A (https=)
NZ (1) NZ598601A (https=)
RU (1) RU2012115480A (https=)
SG (2) SG179027A1 (https=)
WO (1) WO2011033105A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012158818A2 (en) * 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
AR089114A1 (es) 2011-12-09 2014-07-30 Amgen Res Munich Gmbh PREVENCION DE LOS EFECTOS ADVERSOS CAUSADOS POR LOS ANTICUERPOS BIESPECIFICOS EpCAMxCD3
GB201302447D0 (en) 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
SI3889173T1 (sl) 2013-02-15 2023-11-30 Bioverativ Therapeutics Inc. Optimiran gen dejavnika VIII
CN105143270B (zh) * 2013-02-26 2019-11-12 罗切格利卡特公司 双特异性t细胞活化抗原结合分子
ES3012974T3 (en) * 2014-01-08 2025-04-10 Univ Leland Stanford Junior Targeted therapy for lung cancer
EP3160478A4 (en) 2014-06-30 2018-05-16 Bioverativ Therapeutics Inc. Optimized factor ix gene
IL319047A (en) * 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
ES2873846T5 (en) * 2015-11-19 2025-06-23 Revitope Ltd Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
WO2017136358A1 (en) 2016-02-01 2017-08-10 Bioverativ Therapeutics Inc. Optimized factor viii genes
US12128102B2 (en) 2016-03-08 2024-10-29 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
CN109476756B (zh) 2016-03-15 2022-05-31 埃泰美德(香港)有限公司 一种多特异性Fab融合蛋白及其用途
WO2017167350A1 (en) * 2016-03-30 2017-10-05 Horst Lindhofer Multispecific antibodies for use in the treatment of a neoplasm of the urinary tract
EP3409322A1 (en) * 2017-06-01 2018-12-05 F. Hoffmann-La Roche AG Treatment method
IL302613B2 (en) * 2017-09-08 2025-04-01 Maverick Therapeutics Inc Binding proteins are activated under limited conditions
EP3847196A4 (en) 2018-09-07 2023-01-04 ITabMed (HK) Limited BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
WO2020132810A1 (en) 2018-12-24 2020-07-02 Generon (Shanghai) Corporation Ltd. Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
WO2020181140A1 (en) 2019-03-05 2020-09-10 Maverick Therapeutics, Inc. Constrained conditionally activated binding proteins
JP7803014B2 (ja) 2019-09-30 2026-01-21 バイオベラティブ セラピューティクス インコーポレイテッド レンチウイルスベクター製剤
US12173307B2 (en) 2020-06-24 2024-12-24 Bioverativ Therapeutics Inc. Methods for the purification of viral vectors
MX2024006079A (es) * 2021-11-19 2024-07-29 Wuhan Yzy Biopharma Co Ltd Anticuerpo biespecifico y uso del mismo.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
DE602004030811D1 (de) 2003-10-16 2011-02-10 Micromet Ag Multispezifische deimmunisierte cd3-bindende moleküle
CA2606081C (en) * 2005-04-26 2013-09-17 Markus M. Heiss Combination of the application of antibodies for immunostimulation together with glucocorticoids

Also Published As

Publication number Publication date
CA2774732A1 (en) 2011-03-24
NZ598601A (en) 2014-05-30
EP2477653A1 (en) 2012-07-25
SG179027A1 (en) 2012-04-27
KR20120083359A (ko) 2012-07-25
SG10201405434VA (en) 2014-10-30
CN102711825A (zh) 2012-10-03
IN2012DN03172A (https=) 2015-09-25
BR112012008345A2 (pt) 2016-08-09
JP2013505223A (ja) 2013-02-14
RU2012115480A (ru) 2013-10-27
MX2012003175A (es) 2012-04-11
WO2011033105A1 (en) 2011-03-24
US20120244161A1 (en) 2012-09-27
AU2010297258A1 (en) 2012-03-29

Similar Documents

Publication Publication Date Title
IL218637A0 (en) Dosage regimen for administering an epcamxcd3 bispecific antibody
IL219301A (en) A method of determining dosage for the administration of a biphasic 3xcd19cd antibody
HRP20181254T1 (hr) Režim doziranja za multiplu sklerozu
LT2794626T (lt) E selektino antagonisto junginiai
IL225953A0 (en) An antidote–her@@pan
IL229254A0 (en) Therapeutic antibodies
EP2534178A4 (en) THERAPEUTIC PROCEDURES WITH TI-CD200 ANTIBODIES
IL305583B2 (en) Formulation for anti-alpha 4 antibody in cell 7
PL2636736T3 (pl) Nowe przeciwciało anty-dr5
ZA201404270B (en) Dosage regimen of an s1p receptor modulator
ZA201206529B (en) Antigen priteins specific for serum amyloid p component
ZA201402283B (en) Dosage regimen for an s1p receptor modulator or agonist
EP2707392A4 (en) MONOCLONAL ANTIBODY FOR ACETYLAMANTADINE
GB201108529D0 (en) Contrast agents for biophotonic imaging
HK1170940A (en) Dosage regimen for administering an epcamxcd3 bispecific antibody
ZA201308992B (en) Therapeutic antibodies